Yaz 28 Shortage: What Providers and Prescribers Need to Know in 2026

Oral contraceptive supply disruptions have become an increasingly common source of patient calls and care gaps over the past several years. While Yaz 28 (drospirenone/ethinyl estradiol 3 mg/0.02 mg) is not currently listed on the FDA Drug Shortage Database, prescribers are still fielding calls from patients who cannot fill their prescriptions at their usual pharmacy.

This briefing covers the current supply landscape for Yaz 28, the prescribing strategies that minimize patient disruption, therapeutic alternatives for different clinical indications, and tools you can share with patients to help them find their medication.

Current Supply Status (2026)

As of 2026, Yaz 28 and its generic equivalents (drospirenone/ethinyl estradiol 3 mg/0.02 mg) are not on the FDA shortage list. Multiple manufacturers produce AB-rated generics, including Loryna, Nikki, Gianvi, Syeda, Jasmiel, Lo-Zumandimine, Vestura, and Ocella. National supply is stable.

However, localized pharmacy-level stock-outs continue to affect patient access. The root causes include just-in-time pharmacy ordering practices, regional wholesale distributor variability, and pharmacy stocking preferences among the nine or more generics. Patients may find that one chain pharmacy is out while an independent pharmacy two miles away has it in stock.

Prescribing Strategy: Write Generic to Maximize Fill Flexibility

The single most effective step you can take to minimize patient fill problems is to write prescriptions using the generic name rather than the brand:

Write: drospirenone/ethinyl estradiol 3 mg/0.02 mg — 28-day pack (24 active/4 inert) — dispense as generic

This gives pharmacists maximum flexibility to fill with whichever AB-rated generic they have in stock. Avoid "Dispense as Written" (DAW) unless there is a documented clinical reason (e.g., a patient-specific intolerance to inactive ingredients in certain generics).

Clinical Indications and Therapeutic Alternatives

The appropriate alternative depends on your patient's primary indication:

Contraception Only

If contraception is the sole indication, any combined oral contraceptive (COC) with proven efficacy is an acceptable substitute. Options with broad availability and generic pricing include:

Sprintec (norgestimate 0.25 mg/EE 0.035 mg) — among the most widely stocked generic COCs in the U.S.; generic available as Ortho-Cyclen

Junel Fe / Larin Fe (norethindrone acetate/EE) — low-estrogen options available in multiple strengths; widely stocked

Levora / Portia (levonorgestrel/EE) — among the most available and affordable generic COCs; note lower VTE profile vs. DRSP-containing pills

PMDD

Yaz 28 is one of only a few FDA-approved treatments for PMDD. The drospirenone component's anti-mineralocorticoid activity is thought to contribute to reduction in fluid retention and mood-related symptoms. When switching away from drospirenone is necessary:

Beyaz (drospirenone 3 mg/EE 0.02 mg/levomefolate 0.451 mg) — same DRSP/EE formula as Yaz, FDA-approved for PMDD; first-line substitution when Yaz generics unavailable

SSRIs (fluoxetine, sertraline, paroxetine) — first-line pharmacologic treatment for PMDD per ACOG guidelines; FDA-approved for PMDD and effective when COC is contraindicated or unavailable

Hormonal Acne

Yaz 28 is FDA-approved for moderate acne in patients 14+. The anti-androgenic activity of drospirenone is key. Alternatives with FDA acne indication include:

Beyaz — same drospirenone/EE formula, also FDA-approved for acne

Sprintec (norgestimate/EE) — also FDA-approved for moderate acne; widely available as a generic

Alesse / Aviane (levonorgestrel/EE 0.1/0.02 mg) — FDA-approved for acne; low-estrogen option

VTE Risk Counseling When Switching

When counseling patients about switching, be aware that drospirenone-containing COCs may carry a higher VTE risk than levonorgestrel-containing pills — some studies suggest up to a 3-fold increase compared to levonorgestrel formulations. If switching a patient to a levonorgestrel-containing COC, this may actually represent a VTE risk reduction. Conversely, if a patient is switching from a levonorgestrel pill to Yaz 28 or a generic, counsel on VTE risk, particularly during the first 6 months.

Hyperkalemia Monitoring: A Drospirenone-Specific Consideration

Drospirenone has anti-mineralocorticoid activity and can increase serum potassium. Yaz 28 is contraindicated in patients with kidney, liver, or adrenal disease. For patients on chronic medications that also elevate potassium (NSAIDs, ACE inhibitors, ARBs, potassium-sparing diuretics), check serum potassium during the first treatment cycle. When switching from a non-drospirenone COC to Yaz 28, this monitoring requirement applies from the start.

How to Help Patients Find Yaz 28 in Stock

Directing patients to medfinder.com can save significant back-office time. medfinder calls pharmacies near the patient to find which ones have the medication in stock and texts results directly to the patient — without requiring your staff to make calls. For practices dealing with frequent oral contraceptive fill issues, this tool can meaningfully reduce inbound calls.

Summary and Clinical Takeaways

Yaz 28 is not on the FDA shortage list in 2026; national supply is stable

Write generically (drospirenone/EE 3/0.02 mg) to give pharmacists maximum fill flexibility

Beyaz is the closest therapeutic substitute for PMDD and acne indications

Counsel on drospirenone-specific VTE and hyperkalemia risks when initiating or switching

Direct patients to medfinder.com to find in-stock pharmacies without burdening your staff